Peter R. Blower

994 total citations
33 papers, 742 citations indexed

About

Peter R. Blower is a scholar working on Surgery, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Peter R. Blower has authored 33 papers receiving a total of 742 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Surgery, 12 papers in Pharmacology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Peter R. Blower's work include Nausea and vomiting management (15 papers), Inflammatory mediators and NSAID effects (11 papers) and Anesthesia and Pain Management (5 papers). Peter R. Blower is often cited by papers focused on Nausea and vomiting management (15 papers), Inflammatory mediators and NSAID effects (11 papers) and Anesthesia and Pain Management (5 papers). Peter R. Blower collaborates with scholars based in United Kingdom, United States and Switzerland. Peter R. Blower's co-authors include Matti Aapro, Ronald de Wit, Susan Goodin, Michael Day, Richard Melarange, Celeste Lindley, Stéphane Milano, Laurent Grélot, Romain Didier and Philip T. Davey and has published in prestigious journals such as Cancer, Journal of Pharmacology and Experimental Therapeutics and European Journal of Cancer.

In The Last Decade

Peter R. Blower

33 papers receiving 698 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter R. Blower United Kingdom 17 362 162 146 112 95 33 742
James C. Kisicki United States 17 166 0.5× 90 0.6× 107 0.7× 77 0.7× 89 0.9× 28 789
N. Baber United Kingdom 18 164 0.5× 324 2.0× 166 1.1× 55 0.5× 67 0.7× 34 1.1k
Ulla Lei Larsen Denmark 9 166 0.5× 86 0.5× 71 0.5× 65 0.6× 90 0.9× 18 510
Ram P. Kapil United States 14 118 0.3× 145 0.9× 71 0.5× 35 0.3× 60 0.6× 46 731
Lars-Olof Eriksson Sweden 9 252 0.7× 82 0.5× 64 0.4× 40 0.4× 57 0.6× 9 428
V. A. John Switzerland 17 74 0.2× 87 0.5× 158 1.1× 58 0.5× 76 0.8× 34 716
R. G. Cooper United Kingdom 8 182 0.5× 55 0.3× 141 1.0× 78 0.7× 42 0.4× 10 744
J.F. Horga Spain 17 92 0.3× 122 0.8× 85 0.6× 63 0.6× 88 0.9× 47 729
Jerome R. Ryan United States 14 141 0.4× 82 0.5× 242 1.7× 21 0.2× 73 0.8× 36 607
Q-Y Yue Sweden 10 131 0.4× 81 0.5× 75 0.5× 81 0.7× 94 1.0× 12 644

Countries citing papers authored by Peter R. Blower

Since Specialization
Citations

This map shows the geographic impact of Peter R. Blower's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter R. Blower with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter R. Blower more than expected).

Fields of papers citing papers by Peter R. Blower

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter R. Blower. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter R. Blower. The network helps show where Peter R. Blower may publish in the future.

Co-authorship network of co-authors of Peter R. Blower

This figure shows the co-authorship network connecting the top 25 collaborators of Peter R. Blower. A scholar is included among the top collaborators of Peter R. Blower based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter R. Blower. Peter R. Blower is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Blower, Peter R., Ronald de Wit, Susan Goodin, & Matti Aapro. (2005). Drug–drug interactions in oncology: Why are they important and can they be minimized?. Critical Reviews in Oncology/Hematology. 55(2). 117–142. 130 indexed citations
2.
Wit, Ronald de, Matti Aapro, & Peter R. Blower. (2005). Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?. Cancer Chemotherapy and Pharmacology. 56(3). 231–238. 31 indexed citations
3.
Blower, Peter R.. (2003). Granisetron: relating pharmacology to clinical efficacy. Supportive Care in Cancer. 11(2). 93–100. 34 indexed citations
4.
Blower, Peter R.. (2002). 5-HT3-Receptor Antagonists and the Cytochrome P450 System. The Cancer Journal. 8(5). 405–413. 51 indexed citations
5.
Blower, Peter R., et al.. (1999). Effect of Granisetron on Performance Status during High-Dose Interferon Therapy. Oncology. 57(4). 303–305. 3 indexed citations
6.
Grélot, Laurent, Hervé Le Stunff, Stéphane Milano, Peter R. Blower, & Romain Didier. (1996). Repeated administration of the 5-HT3 receptor antagonist granisetron reduces the incidence of delayed cisplatin-induced emesis in the piglet.. Journal of Pharmacology and Experimental Therapeutics. 279(1). 255–261. 18 indexed citations
7.
Blower, Peter R.. (1995). A pharmacologic profile of oral granisetron (Kytril tablets).. PubMed. 22(4 Suppl 10). 3–5. 18 indexed citations
8.
Melarange, Richard, et al.. (1994). Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Digestive Diseases and Sciences. 39(3). 601–608. 16 indexed citations
9.
Davey, Philip T., et al.. (1994). The antiemetic activity of granisetron against cytostatic-treatment-induced emesis in 10- to 13-week-old ferrets. Journal of Cancer Research and Clinical Oncology. 120(4). 204–207. 2 indexed citations
10.
Davey, Philip T., et al.. (1994). Further Studies of the Antiemetic Activity of Granisetron against Whole Body X-lrradiation or Cisplatin-lnduced Emesis in the Ferret. Pharmacology. 48(5). 283–292. 6 indexed citations
11.
Blower, Peter R.. (1993). Non-Steroidal Anti-Inflammatory Drugs. Lara D. Veeken. 32(suppl 4). 35–38. 9 indexed citations
12.
Melarange, Richard, et al.. (1992). A comparison of indomethacin with ibuprofen on gastrointestinal mucosal integrity in conventional and germ‐free rats. Alimentary Pharmacology & Therapeutics. 6(1). 67–77. 29 indexed citations
13.
Melarange, Richard, et al.. (1992). Antiinflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Digestive Diseases and Sciences. 37(12). 1847–1852. 21 indexed citations
14.
Melarange, Richard, Clive Gentry, Caroline O’Connell, et al.. (1992). Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6MNA (6-methoxy-2-naphthylacetic acid): Comparison with indomethacin. Inflammation Research. 36(3-4). C82–C83. 6 indexed citations
15.
Andrews, Paul, et al.. (1992). Are all 5-HT3 receptor antagonists the same?. European Journal of Cancer. 28. S2–S6. 68 indexed citations
16.
Blower, Peter R.. (1991). The science--equivalent efficacy and diminished risk.. PubMed. 11(3). 29–37. 4 indexed citations
17.
Melarange, Richard, Clive Gentry, Caroline O’Connell, & Peter R. Blower. (1991). Anti-Inflammatory Efficacy and Gastrointestinal Irritancy: Comparative 1 Month Repeat Oral Dose Studies in the Rat with Nabumetone, Ibuprofen and Diclofenac. Birkhäuser Basel eBooks. 32. 33–37. 9 indexed citations
18.
Blower, Peter R.. (1990). The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis.. PubMed. 26 Suppl 1. S8–11. 40 indexed citations
19.
Blower, Peter R., et al.. (1976). Effects of α-methyldopa on blood pressure in the anaesthetized dog. Journal of Pharmacy and Pharmacology. 28(5). 437–440. 4 indexed citations
20.
Day, Michael & Peter R. Blower. (1975). Cardiovascular dopamine receptor stimulation antagonized by metoclopramide. Journal of Pharmacy and Pharmacology. 27(4). 276–278. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James C. Kisicki Breakdown of academic impact, for papers by N. Baber Breakdown of academic impact, for papers by Ulla Lei Larsen Breakdown of academic impact, for papers by Ram P. Kapil Breakdown of academic impact, for papers by Lars-Olof Eriksson Breakdown of academic impact, for papers by V. A. John Breakdown of academic impact, for papers by R. G. Cooper Breakdown of academic impact, for papers by J.F. Horga Breakdown of academic impact, for papers by Jerome R. Ryan Breakdown of academic impact, for papers by Q-Y Yue
Rankless by CCL
2026